{"disease":{"id":"metastatic-anal-canal-carcinoma","name":"metastatic anal canal carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03439085","title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02314169","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04221893","title":"Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of California, San Francisco","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}